Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 16, Number 3—March 2010

Research

Vaccine Preventability of Meningococcal Clone, Greater Aachen Region, Germany

Johannes EliasComments to Author , Leo M. Schouls, Ingrid van de Pol, Wendy C. Keijzers, Diana R. Martin, Anne Glennie, Philipp Oster, Matthias Frosch, Ulrich Vogel1, and Arie van der Ende1
Author affiliations: University of Wuerzburg, Wuerzburg, Germany (J. Elias, M. Frosch, U. Vogel); National Institute for Public Health and Environment (RIVN), Bilthoven, the Netherlands (L.M. Schouls, I. van de Pol); Academic Medical Center, Amsterdam, the Netherlands (W.C. Keijzers, A. van der Ende); Institute of Environmental Science and Research, Porirua, New Zealand (D.R. Martin, A. Glennie); Novartis Vaccines, Siena, Italy (P. Oster)

Main Article

Table 2

Serum bactericidal antibody titers before and after vaccination with MeNZB against German strain DE9686, Greater Aachen Region, Germany, 2001–2006*

Age group No. vaccinees Before After 4-fold rise >8 post
8–12 y 1 12 1,727 ← ←
2 3 104 ← ←
3 189 406 – ←
4 50 296 ← ←
5 229 729 – ←
6 23 175 ← ←
7 9 84 ← ←
8 2 213 ← ←
9 2 77 ← ←
10 2 55 ← ←
18–24 mo 11 2 214 ← ←
12 4 45 ← ←
13 2 109 ← ←
14 7 92 ← ←
15 2 306 ← ←
16 6 431 ← ←
17 2 216 ← ←
18 3 44 ← ←
19 3 218 ← ←
20 2 171 ← ←

*– represents cases where conditions 4-fold rise and >8 post are false. Arrows represent cases where conditions 4-fold rise and >8 post are true.

Main Article

1These authors contributed equally to this article.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO